Print this page

Autoimmunity - Partnership Meeting Breakout Session

AID Breakout session The meeting started on Wednesday afternoon, May 24th, with a breakout session featuring an opening lecture delivered by our partner Ruwag. The purpose of the lecture was to celebrate the successful deployment of the new Aptiva technology at two AID centers located in Switzerland. We then proceeded with a presentation on our achievements in 2022, with a special focus on our recent Autoimmunity Review publication about the 9th Werfen International Autoimmunity seminar. We concluded the meeting with updates on the Integrated Lab and BIO-FLASH.

Thursday morning commenced with the AID Call to Action and the unveiling of the Marketing plan for 2023. Subsequently, our attention shifted towards the highly anticipated Aptiva® platform. Following an introduction to the innovative PMAT (Particle-based Multi Analyte) technology, we delved into an elaborate discussion of the array of new analytes that will be introduced on the platform. The analysis of these autoantibodies will play a crucial role in assisting laboratorians and clinicians in bridging the "seronegative" gap often encountered in autoimmune disorders. Moreover, the profiling of different autoantibodies will prove instrumental in the stratification of patients with autoimmune-related conditions.

The focus group proceeded with a comprehensive comparison between the Aptiva platform and our primary competitors, Bio-Rad and Phadia. Additionally, there was a brief discussion concerning the reimbursement strategy pertaining to novel biomarkers. Subsequently, we delved into the latest parameters available on BIO- FLASH®, emphasizing the advantages and strengths of QUANTA Flash® Circulating Calprotectin. We also had the opportunity to hear a success story about the effective implementation of the Calprotectin test in the Czech Republic. The session further encompassed updates on Quanta Link and provided insights into the new Werfen Service program, which focuses on learning and development. To conclude the meeting, we showcased a selection of our ongoing collaborations and studies taking place in various hospitals, all aimed at reinforcing the value of our biomarkers on both BIO-FLASH and Aptiva platforms.

The success of the meeting was ensured by the participation of all our partners from the EEMEA geographies. Additionally, we received great support from Werfen AID SBU, including Sofia Afonso - Marketing Manager, Amy Peterson - Service Director AID, and Mary Ann Aure - Clinical Affairs AID.

Thank you to all the participants for their contributions!

Autoimmunity Marketing Team, EEMEA

Last modified on Thursday, 08 June 2023 06:17